PCVX Vaxcyte Inc

$PCVX Phase 3 data here tomorrow. Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate "will host a webcast and conference call tomorrow, October 5, 2026 at 8:00 a.m. ET / 5:00 a.m. PT to present topline data from the OPUS-1 adult pivotal Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia."

$PCVX TAM is huge for this. Company/product family 2025 sales Pfizer Prevnar family $6.49bn Merck Capvaxive $759M Merck Vaxneuvance $825M Merck Pneumovax 23 $166M Global PCV market ~$8.5bn

$PCVX how cubie know pcvx aint gonna pull $MRNA $KOD and go up 150-200% like.the useless pumptards thought. cubie teaches

$PCVX Ugly puking, down 34% from premarket high...remembers me of $MLTX puking on jun 26 of 2023, it went to 103 in premarket to open at about 50...since then is total shit.

$PCVX Definitely pretty impressive but, from my experience it has a lot to do with who the book runners are

$PCVX Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

$PCVX this stupid tard watched it go from 50s to 108. thank god no one was stupid enough to short it on 9/15 when u said so. smart peeps followed cubie treasure trove and shorted it yesterday in $80-$90.

$PCVX it’s back at where is was before that Phrase 3 PR lmao 🤣………… nothing really happen except they stole $1,000,000,000 from investors hahah. Wow I thought all micro cap fraud scam stocks only does that. But PCVX a billion$ market cap company are doing the same scam moves like small micro cap scam stocks doing hahhahahaha. $60…40 sooon im sorry smh

$PCVX Problems with serotypes 3, 4, 12F, 19F and 22F, consistency manufacturing, coverage not as good as capvaxive, will struggle against Pfizer and Merck.

$PCVX that didn't take long Vaxcyte commenced a $500M common stock and pre-funded warrant offering plus $500M of convertible senior notes due 2032, each with a $75M upsize option. Proceeds fund the rest of the VAX-31 adult and infant programs, manufacturing scale-up and U.S. launch prep.

$PCVX burning $$$ and this isn't approval - best p&d today .....sub 50 soon due to heavy shorting ;)

$PCVX I've got my buy stop already set. But for all the bulls out there or anyone thinking of entering long; please read their last quarterly statement. They are burning through cash AND have an active ATM program with a history of using it in the open market. They don't need to file to dilute and they need cash.

$PCVX PCVX is still a clinical-stage biotech with no approved VAX-31 product and significant regulatory/commercial execution ahead

$PCVX My favorite Press Release today: Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate On watch to see if we can have a $MRNA like move from last month!

$PCVX Congrats here VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21)

$PCVX congrats to longs on the convincing phase 3 data win 👏 All primaries met, even superiority on a few STs. Good for sector sentiment $XBI Have to give credit to as well, for sticking to his convictions as usual & laying his thesis out ahead of time. Respect

$PCVX is active on clinical trial results following a Globe Newswire release. Vaxcyte's VAX-31 pneumococcal vaccine met all primary endpoints in Phase 3 OPUS-1 trial, showing noninferiority to competitors with superior immune response for unique serotypes. RTPR pushed this release out to users at 6:00:00 AM ET

$PCVX Price: $66.7 Volume: Above average Catalyst: Ongoing VAX-31 pivotal trial updates and anticipation of pneumococcal vaccine data keep speculative interest elevated. Resistance: $72 Support: $62 Bull case: A clean break above $72 on strong volume could fuel a run toward prior highs as traders price in trial optimism. Bear case: Failure to hold $62 support may trigger a slide toward $55 if momentum fades and profit-taking kicks in. What I'm watching: Watching for a decisive close above $72 with sustained volume to confirm bullish continuation. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services.

$PCVX yesterday wasn't good but i knew they wont go far! they needed money and hence shorted more ..this will take time to cross the boundry..

$PCVX - lotta shorts at open- - lotta shorts yesterday - probably be some covering today… good stock to trade here…